Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
19
11
2020
accepted:
01
04
2021
revised:
29
04
2021
pubmed:
20
4
2021
medline:
24
8
2021
entrez:
19
4
2021
Statut:
epublish
Résumé
HIV-1 infects CD4 T lymphocytes (CD4TL) through binding the chemokine receptors CCR5 or CXCR4. CXCR4-using viruses are considered more pathogenic, linked to accelerated depletion of CD4TL and progression to AIDS. However, counterexamples to this paradigm are common, suggesting heterogeneity in the virulence of CXCR4-using viruses. Here, we investigated the role of the CXCR4 chemokine CXCL12 as a driving force behind virus virulence. In vitro, CXCL12 prevents HIV-1 from binding CXCR4 and entering CD4TL, but its role in HIV-1 transmission and propagation remains speculative. Through analysis of thirty envelope glycoproteins (Envs) from patients at different stages of infection, mostly treatment-naïve, we first interrogated whether sensitivity of viruses to inhibition by CXCL12 varies over time in infection. Results show that Envs resistant (RES) to CXCL12 are frequent in patients experiencing low CD4TL levels, most often late in infection, only rarely at the time of primary infection. Sensitivity assays to soluble CD4 or broadly neutralizing antibodies further showed that RES Envs adopt a more closed conformation with distinct antigenicity, compared to CXCL12-sensitive (SENS) Envs. At the level of the host cell, our results suggest that resistance is not due to improved fusion or binding to CD4, but owes to viruses using particular CXCR4 molecules weakly accessible to CXCL12. We finally asked whether the low CD4TL levels in patients are related to increased pathogenicity of RES viruses. Resistance actually provides viruses with an enhanced capacity to enter naive CD4TL when surrounded by CXCL12, which mirrors their situation in lymphoid organs, and to deplete bystander activated effector memory cells. Therefore, RES viruses seem more likely to deregulate CD4TL homeostasis. This work improves our understanding of the pathophysiology and the transmission of HIV-1 and suggests that RES viruses' receptors could represent new therapeutic targets to help prevent CD4TL depletion in HIV+ patients on cART.
Identifiants
pubmed: 33872329
doi: 10.1371/journal.ppat.1009526
pii: PPATHOGENS-D-20-02505
pmc: PMC8084328
doi:
Substances chimiques
Antiviral Agents
0
CXCL12 protein, human
0
CXCR4 protein, human
0
Chemokine CXCL12
0
Receptors, CXCR4
0
Viral Envelope Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009526Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Infect Dis. 2005 Aug 1;192(3):466-74
pubmed: 15995960
PLoS Pathog. 2018 Dec 6;14(12):e1007432
pubmed: 30521629
Immunity. 2017 Sep 19;47(3):524-537.e3
pubmed: 28916265
J Virol. 2008 Aug;82(16):7932-41
pubmed: 18524815
Cell Death Dis. 2010 Nov 11;1:e99
pubmed: 21368875
J Virol Methods. 2016 Oct;236:184-195
pubmed: 27451265
Mol Cell. 2018 Apr 5;70(1):106-119.e10
pubmed: 29625032
Trends Microbiol. 2005 Jun;13(6):269-77
pubmed: 15936659
J Exp Med. 2004 Nov 15;200(10):1299-314
pubmed: 15545355
J Virol. 2007 Jan;81(2):525-31
pubmed: 17079299
Biochem Biophys Res Commun. 2012 Jan 6;417(1):409-13
pubmed: 22166195
Trends Microbiol. 2019 Oct;27(10):878-891
pubmed: 31262533
J Antimicrob Chemother. 2017 Oct 1;72(10):2862-2868
pubmed: 29091208
J Histochem Cytochem. 2019 Apr;67(4):257-266
pubmed: 30562126
Nature. 2018 Jul;559(7712):45-53
pubmed: 29973731
J Virol. 1989 May;63(5):2118-25
pubmed: 2564898
Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9475-80
pubmed: 23696662
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):376-9
pubmed: 26959188
Chem Biol. 2012 Jan 27;19(1):131-9
pubmed: 22284360
Immunity. 2014 May 15;40(5):669-80
pubmed: 24768348
AIDS. 2010 Aug 24;24(13):2051-8
pubmed: 20601851
J Infect Dis. 2005 Mar 15;191(6):866-72
pubmed: 15717260
Ann Intern Med. 1993 May 1;118(9):681-8
pubmed: 8096374
J Immunol. 2002 Mar 15;168(6):2609-17
pubmed: 11884424
Immunity. 2015 Nov 17;43(5):959-73
pubmed: 26588781
Cell Host Microbe. 2016 Mar 9;19(3):280-91
pubmed: 26962940
J Immunol Methods. 2015 Jul;422:102-10
pubmed: 25910833
AIDS. 2003 Sep 5;17(13):1871-9
pubmed: 12960819
J Virol. 1994 Dec;68(12):8188-92
pubmed: 7966610
J Leukoc Biol. 2020 Jun;107(6):1123-1135
pubmed: 32374043
Nature. 2014 Oct 23;514(7523):455-61
pubmed: 25296255
Retrovirology. 2015 Jun 18;12:50
pubmed: 26081316
J Biol Chem. 2014 Jul 4;289(27):19042-52
pubmed: 24855645
Retrovirology. 2016 Jul 30;13(1):50
pubmed: 27473399
Immunol Rev. 2013 Jul;254(1):54-64
pubmed: 23772614
Int J Biochem Cell Biol. 2018 Feb;95:121-131
pubmed: 29288743
Trends Immunol. 2012 Jun;33(6):306-14
pubmed: 22613276
Nat Med. 1999 Mar;5(3):344-6
pubmed: 10086394
J Virol. 2007 Jan;81(2):893-902
pubmed: 17093193
EMBO J. 1997 Dec 1;16(23):6996-7007
pubmed: 9384579
AIDS. 2018 Sep 10;32(14):1917-1926
pubmed: 29927786
J Virol. 2011 Aug;85(16):8227-40
pubmed: 21680525
J Virol. 2004 Mar;78(6):2722-8
pubmed: 14990692
J Virol. 2004 Feb;78(4):2121-30
pubmed: 14747577
Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1269-74
pubmed: 10655520
Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12324-9
pubmed: 15297611
J Immunol. 2002 Apr 15;168(8):4121-6
pubmed: 11937572
Science. 2013 Dec 20;342(6165):1477-83
pubmed: 24179159
Structure. 2019 Jan 2;27(1):196-206.e6
pubmed: 30471922
Virology. 2009 Aug 1;390(2):348-55
pubmed: 19539340
J Infect Dis. 2003 Sep 15;188(6):864-72
pubmed: 12964118
J Clin Virol. 2010 Feb;47(2):126-30
pubmed: 20015684
J Biol Chem. 2010 May 14;285(20):15566-15576
pubmed: 20228059
J Virol. 2010 May;84(9):4341-51
pubmed: 20181695
Proc Natl Acad Sci U S A. 2014 May 13;111(19):E1960-9
pubmed: 24778234
Immunity. 2018 May 15;48(5):855-871
pubmed: 29768174
Nat Med. 1997 Nov;3(11):1259-65
pubmed: 9359702
mBio. 2016 Oct 25;7(5):
pubmed: 27795397
Nature. 2014 Jan 23;505(7484):509-14
pubmed: 24356306
J Virol. 1999 Aug;73(8):6598-609
pubmed: 10400757
J Virol. 2002 Apr;76(7):3114-24
pubmed: 11884536
Virology. 1996 May 1;219(1):87-95
pubmed: 8623557
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
pubmed: 18490657
Nature. 2019 Apr;568(7752):415-419
pubmed: 30971821
Immunol Rev. 2013 Jul;254(1):78-101
pubmed: 23772616
J Virol. 2001 Oct;75(19):8957-67
pubmed: 11533159
Cell Metab. 2019 Mar 5;29(3):611-626.e5
pubmed: 30581119
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
pubmed: 4202581
Curr Biol. 2000 Mar 23;10(6):325-8
pubmed: 10744978
J Exp Med. 2000 Aug 7;192(3):313-24
pubmed: 10934220
Mol Pharmacol. 2005 Jun;67(6):1966-76
pubmed: 15761117
Immunity. 2017 Apr 18;46(4):690-702
pubmed: 28423342
J Exp Med. 1997 Jul 7;186(1):139-46
pubmed: 9207008
Viruses. 2017 Aug 22;9(8):
pubmed: 28829402
J Exp Med. 1997 Jan 6;185(1):111-20
pubmed: 8996247
J Virol. 2000 Apr;74(7):3196-204
pubmed: 10708436
Biochemistry. 2008 Oct 28;47(43):11251-62
pubmed: 18834145
Nat Med. 2010 Apr;16(4):446-51
pubmed: 20208541
J Virol. 2005 Feb;79(3):1930-3
pubmed: 15650218
Nat Commun. 2017 Oct 19;8(1):1049
pubmed: 29051495